The management of pituitary tumours and post-operative visual deterioration.
The indications and results of transsphenoidal surgery for pituitary adenomas are analysed. The advantages and disadvantages of Bromocriptine and radiotherapy are considered. Transsphenoidal surgery does not damage pre-existing pituitary function. It produces excellent results in micro and mesoadenomas, curing about 70-80% of patients irrespective whether the tumour produces ACTH, prolactin or growth hormone. Moreover there is a very small relapse rate. Macroadenomas of non-functioning type are also well treated by transphenoidal surgery, with a small recurrence rate as judged by CT scan follow-up. But macroadenomas secreting prolactin or growth hormone are less effectively treated by transsphenoidal surgery, only about 40% being cured. Invasive macro prolactinomas are not helped by surgery and should be treated with Bromocriptine and radiotherapy. Radiotherapy should be used sparingly and has inevitable complications. Post-operative delayed visual deterioration is caused either by recurrent tumour or radiotherapy. There is no good evidence to support the secondary empty sella syndrome as a cause of such delayed visual deterioration.
Adams
C B
CB
Department of Neurological Surgery, Radcliffe Infirmary, Oxford, U.K.
D000236:Adenoma / Q000601:surgery*; D004739:England; D013006:Growth Hormone / Q000378:metabolism; D049673:History, 20th Century; D006801:Humans; D009493:Neurosurgery / Q000266:history; D010911:Pituitary Neoplasms / Q000601:surgery*; D011183:Postoperative Complications / Q000209:etiology*; D011388:Prolactin / Q000378:metabolism; D014786:Vision Disorders / Q000209:etiology*
D011388:Prolactin; D013006:Growth Hormone